Spots Global Cancer Trial Database for urologic neoplasms
Every month we try and update this database with for urologic neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | NCT00035061 | Urologic Neopla... Metastases, Neo... | pemetrexed | 18 Years - | Eli Lilly and Company | |
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| LPN in Patients With High-complex Renal Tumors | NCT04933604 | Renal Cancer Renal Neoplasm Renal Cell Carc... Surgery Oncology Kidney Ischemia Kidney Injury Urologic Neopla... Urologic Cancer Kidney Neoplasm... | laparoscopic pa... Laparoscopic ra... | 18 Years - 80 Years | Samsun Liv Hospital | |
| Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer | NCT00226954 | Urologic Neopla... | zoledronic acid | 18 Years - | Stanford University | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| Savolitinib vs. Sunitinib in MET-driven PRCC. | NCT03091192 | Carcinoma Carcinoma, Rena... Kidney Neoplasm... Urologic Neopla... Kidney Diseases Neoplasms by Si... Enzyme Inhibito... Protein Kinase ... | Savolitinib Sunitinib | 18 Years - 130 Years | AstraZeneca | |
| 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | NCT00191971 | Urologic Neopla... Carcinoma, Tran... | Gemcitabine | 20 Years - 74 Years | Eli Lilly and Company | |
| A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery | NCT03010813 | Colorectal Neop... Urologic Neopla... Urologic Diseas... Nasopharyngeal ... Oropharyngeal N... Oral Neoplasms Hypopharyngeal ... Laryngeal Neopl... ENT Diseases | Robotic single ... | 18 Years - | Chinese University of Hong Kong | |
| Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy | NCT05887245 | Renal Cell Carc... Kidney Neoplasm Urologic Neopla... Urogenital Neop... Kidney Diseases | 18 Years - | Centre of Postgraduate Medical Education | ||
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | NCT00384891 | Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000). | NCT05025930 | Urologic Neopla... | endoscopic surg... endoscopic surg... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy | NCT04442724 | Bladder Cancer Urinary Bladder... Urologic Neopla... Neoplasms Urinary Bladder... | Fiducial marker... Multiparametric... | 18 Years - | Cedars-Sinai Medical Center | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen | NCT05113134 | Colorectal Neop... Urologic Neopla... Gastrointestina... Neoplasms by Si... | Transvaginal na... | 20 Years - | Seoul National University Bundang Hospital | |
| To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery | NCT05308771 | Abdominal Herni... Abdominal Wall ... Abdominal Neopl... Urogenital Dise... Urologic Neopla... Thoracic Diseas... Lung Diseases | VPC syringe | - 16 Years | Centre Hospitalier Universitaire de Tivoli | |
| Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery | NCT04630483 | Cancer Urologic Neopla... Gynecologic Can... | INHA TIVA | 20 Years - 75 Years | Medipol University | |
| Laparoscopic Partial Nephrectomy for cT1 Tumors | NCT04213157 | Renal Cancer Renal Neoplasm Renal Cell Carc... Surgery Surgery--Compli... Renal Functiona... Oncology Oncology Proble... Kidney Ischemia Kidney Injury Urologic Neopla... Urologic Cancer Kidney Neoplasm... | 18 Years - 82 Years | Samsun Liv Hospital | ||
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer | NCT00226954 | Urologic Neopla... | zoledronic acid | 18 Years - | Stanford University | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | NCT01454089 | Urologic Neopla... Metastatic Blad... Urinary Tract N... | OGX-427 600 mg OGX-427 1000 mg Placebo Gemcitabine Cisplatin Carboplatin | 18 Years - | Achieve Life Sciences | |
| Pre-Operative Single Shot Rectus Sheath Block | NCT03458598 | Bladder Neoplas... Prostate Neopla... Pelvic Neoplasm Urologic Neopla... Opioid Use Anesthesia, Loc... Pain, Postopera... | Rectus sheath b... Bilateral rectu... Patient control... Subcutaneous in... | 18 Years - | University of Alberta | |
| Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | NCT01155791 | Urologic Neopla... Prostate Cancer Prostate Cancer... | Docetaxel Biosyn Prednisone | 18 Years - | Stanford University | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| LPN in Patients With High-complex Renal Tumors | NCT04933604 | Renal Cancer Renal Neoplasm Renal Cell Carc... Surgery Oncology Kidney Ischemia Kidney Injury Urologic Neopla... Urologic Cancer Kidney Neoplasm... | laparoscopic pa... Laparoscopic ra... | 18 Years - 80 Years | Samsun Liv Hospital | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study | NCT04702347 | Urologic Cancer Urologic Neopla... | Urine biomarker | 18 Years - | Fundacio Puigvert | |
| Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy | NCT04649970 | Urologic Neopla... | Antegrade doubl... | - | Université de Sousse | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) | NCT04922047 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Antineoplastic ... Urinary Bladder... Tislelizumab An... | tislelizumab an... | 18 Years - 75 Years | RenJi Hospital | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery | NCT04630483 | Cancer Urologic Neopla... Gynecologic Can... | INHA TIVA | 20 Years - 75 Years | Medipol University | |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | NCT01454089 | Urologic Neopla... Metastatic Blad... Urinary Tract N... | OGX-427 600 mg OGX-427 1000 mg Placebo Gemcitabine Cisplatin Carboplatin | 18 Years - | Achieve Life Sciences | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma | NCT04644432 | Metastatic Rena... Kidney Neoplasm Urologic Neopla... Urogenital Neop... | Medication (A s... Patient reporte... | 18 Years - | Herlev and Gentofte Hospital | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | NCT03636256 | Bladder Cancer Urothelial Carc... Urinary Bladder... Urinary Bladder... Urogenital Neop... Urologic Neopla... Urologic Cancer Malignant Tumor... Cancer of the B... | NanoDoce (direc... NanoDoce (intra... Institutional S... NanoDoce (intra... | 18 Years - | NanOlogy, LLC | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer | NCT04052113 | Urologic Neopla... | - | AstraZeneca | ||
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | NCT04300140 | Clear Cell Rena... | Batiraxcept Cabozantinib (C... Nivolumab | 18 Years - | Aravive, Inc. | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen | NCT05135520 | Urologic Neopla... | Transvaginal na... Transabdominal ... | 20 Years - | Seoul National University Bundang Hospital | |
| LPN in Patients With High-complex Renal Tumors | NCT04933604 | Renal Cancer Renal Neoplasm Renal Cell Carc... Surgery Oncology Kidney Ischemia Kidney Injury Urologic Neopla... Urologic Cancer Kidney Neoplasm... | laparoscopic pa... Laparoscopic ra... | 18 Years - 80 Years | Samsun Liv Hospital | |
| A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | NCT05899361 | Urologic Cancer Urologic Neopla... Bladder Cancer Prostate Cancer Testicular Canc... Kidney Cancer Urethral Cancer Penile Cancer | Electromagnetic... Ultrasound | 18 Years - | Dana-Farber Cancer Institute | |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | NCT02307487 | Bladder Cancer Neoplasms Urinary Bladder... Urologic Diseas... | 120 mg MMC in 9... 140 mg MMC in 9... 160 mg MMC in 9... 120 mg MMC in 6... 140 mg MMC in 6... 160 mg MMC in 6... | 18 Years - | UroGen Pharma Ltd. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | NCT04300140 | Clear Cell Rena... | Batiraxcept Cabozantinib (C... Nivolumab | 18 Years - | Aravive, Inc. | |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients | NCT02891460 | Urinary Bladder... Urologic Neopla... Neoplasms Urinary Bladder... Urologic Diseas... | 40 mg MMC in 40... 80 mg MMC in 40... | 18 Years - | UroGen Pharma Ltd. | |
| A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | NCT05899361 | Urologic Cancer Urologic Neopla... Bladder Cancer Prostate Cancer Testicular Canc... Kidney Cancer Urethral Cancer Penile Cancer | Electromagnetic... Ultrasound | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium | NCT00034177 | Urologic Neopla... | S-8184 Paclitax... Experimental Ar... | 18 Years - | Achieve Life Sciences | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00034593 | Urologic Neopla... | ALIMTA gemcitabine | 18 Years - | Eli Lilly and Company | |
| LPN in Patients With High-complex Renal Tumors | NCT04933604 | Renal Cancer Renal Neoplasm Renal Cell Carc... Surgery Oncology Kidney Ischemia Kidney Injury Urologic Neopla... Urologic Cancer Kidney Neoplasm... | laparoscopic pa... Laparoscopic ra... | 18 Years - 80 Years | Samsun Liv Hospital | |
| Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy | NCT04649970 | Urologic Neopla... | Antegrade doubl... | - | Université de Sousse | |
| A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | NCT00753415 | Non-Small Cell ... Breast Cancer Melanoma Upper GI Tract ... Colon Carcinoma Renal Cell Carc... Bladder Carcino... Prostate Cancer | V935 V934-EP | 18 Years - | Merck Sharp & Dohme LLC | |
| Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study | NCT04702347 | Urologic Cancer Urologic Neopla... | Urine biomarker | 18 Years - | Fundacio Puigvert | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| Laparoscopic Partial Nephrectomy for cT1 Tumors | NCT04213157 | Renal Cancer Renal Neoplasm Renal Cell Carc... Surgery Surgery--Compli... Renal Functiona... Oncology Oncology Proble... Kidney Ischemia Kidney Injury Urologic Neopla... Urologic Cancer Kidney Neoplasm... | 18 Years - 82 Years | Samsun Liv Hospital | ||
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00034593 | Urologic Neopla... | ALIMTA gemcitabine | 18 Years - | Eli Lilly and Company | |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | NCT02543645 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms by Hi... Neoplasms Clear-cell Meta... Melanoma Triple Negative... Bladder Cancer Head and Neck C... Non-small Cell ... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer | NCT04052113 | Urologic Neopla... | - | AstraZeneca | ||
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China | |
| Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms | NCT05990621 | CD70-positive A... | Anti-CD70 CAR-T... | 18 Years - | Changhai Hospital | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000). | NCT05025930 | Urologic Neopla... | endoscopic surg... endoscopic surg... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
